TEST:

Haystack MRD™

P=N/A, N=150, Recruiting, City of Hope Medical Center

"Haystack Oncology...today announced a research collaboration with Mass General Brigham investigators at Massachusetts Eye and Ear and Massachusetts General Hospital, world-renowned centers for head and neck and advanced cutaneous oncology. The research collaboration will investigate the use of Haystack MRD™, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease test, as an aid in postoperative therapy decisions for two cancer types: cutaneous squamous cell carcinoma (CSCC), a type of skin cancer, and HPV-independent head and neck squamous cell carcinoma (HNSCC)."

Results of the analytical validation of the MRD test system highlight the robustness and accuracy of the ultra-sensitive tumor-informed Haystack MRD assay, paving the way for its clinical application in detecting residual disease, tracking treatment response, and identifying recurrence in patients with solid tumors.

"Haystack Oncology...announced today a research collaboration with Dr. Simon Turcotte, hepatopancreatobiliary surgeon and scientist at Université de Montréal's affiliated hospital research centre, the CRCHUM, to utilize Haystack Oncology's personalized MRD technology (Haystack MRD) to evaluate treatment effectiveness in patients with metastatic colorectal cancer (mCRC) with metastases confined to the liver. This prospective, observational study, Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients (eDetect), will use Haystack MRD to assess circulating tumor DNA (ctDNA) as an early biological marker of treatment response and disease recurrence in patients with mCRC undergoing systemic treatment and liver surgery with curative intent."

"Haystack’s minimal residual disease (MRD) detection technology was featured in 2 presentations at the 2024 American Society of Clinical Oncology (ASCO) annual meeting this June in Chicago. Dr Andrea Cercek of Memorial Sloan Kettering Cancer Center presented exciting results for a PD-1 blockade drug in treating mismatch repair–deficient rectal cancers, while Dr Jeanne Tie of the Peter MacCallum Cancer Center shared a 5-year update from the DYNAMIC study, which used MRD testing to guide adjuvant chemo decisions."

"A blood test could help reduce costs for health plans by reliably identifying patients who might be able to safely forgo chemotherapy after surgery for stage II colorectal cancer, according to a study published today in JAMA Health Forum, a member of the JAMA Network. Researchers from Haystack Oncology...and Eliza Hall Institute of Medical Research conducted the study."